A new inter partes review filed at the Patent Trial and Appeal Board could be one to watch for companies operating at the intersection of life sciences, nutraceuticals, and consumer health. In IPR2026-00400, the proceeding is captioned Thorne Research, Inc. and was filed on June 22, 2026.

At this early stage, the PTAB docket signals that a patent challenge involving Thorne Research is underway, but practitioners should note that key details—including the specific patent claims at issue, the identity of the petitioner and patent owner as reflected in the styled papers, and the precise invalidity combinations asserted—may develop as the record fills out.

A new inter partes review, IPR2026-00400, was filed on June 22, 2026, at the Patent Trial and Appeal Board against Thorne Research, Inc. The proceeding is one to watch for companies operating at the intersection of dietary supplements, formulations, and health-focused consumer products, where patent value often turns on how broadly claims are drafted and how well they withstand validity attacks based on published prior art.

At this stage, the publicly available docket information identifies Thorne Research, Inc. as the patent owner, but practitioners should review the petition and related filings to confirm the specific challenged patent, the real parties in interest, and the exact claims at issue as the record develops.

A new inter partes review, IPR2026-00391, was filed on June 5, 2026, at the Patent Trial and Appeal Board naming Teladoc Health, Inc. in the proceeding. The filing places another spotlight on the digital health and telemedicine patent landscape, where platform functionality, remote care workflows, and software-driven healthcare delivery continue to generate high-stakes validity disputes.

At this early stage, the PTAB docket identifies the proceeding by title but may not yet reflect the full set of publicly available petition details practitioners typically watch for, including the specific patent number, the complete alignment of petitioner and patent owner, and the precise prior-art combinations asserted in the challenge.

The SEC has settled insider-trading charges against Weizheng Zeng in an administrative proceeding arising from the acquisition of Chimerix, Inc. by Jazz Pharmaceuticals plc. In SEC v. Weizheng Zeng (File No. 3-22627), the agency alleged that Zeng traded Chimerix stock while participating in due diligence work connected to Jazz’s acquisition of the company, before the deal was publicly announced on March 5, 2025.

According to the SEC, those trades generated roughly $69,011 in illicit profits.